Thursday, June 21, 2018 3:43:24 PM
As regular trading ended, ReShape Lifesciences Inc. (RSLS) stock brought in a -$0.75 drop to $2.49. The day started at a price of $2.8 but then traded as high as $2.85 before giving part of the gains back. As for this week, analysts appear content to stick with their bright outlook with the consensus call at 1. ReShape Lifesciences Inc. is given 1 buy-equivalent recommendations, 0 sells and 0 holds. The company shares sank -96.86% from their peak of $79.20 and now has a $6.15 million market value of equity.
ReShape Lifesciences Inc. Could Grow 1185.14% More
RSLS’s mean recommendation on Reuter’s scale presents no change from 1 thirty days ago to 1 now, which indicates a buy consensus from the analyst community. They see ReShape Lifesciences Inc. (RSLS) price hitting a mean target of $32 a share, meaning the stock still has potential that could lift the price another 1185.14% Also, the recent close suggests the stock is underpriced by 1185.14% compared to the most bullish target.
ReShape Lifesciences Inc. (RSLS) Returns -88.78% This Year
The company had seen its current volume reaching at 1.06 million shares in the last trade. That compares with the recent volume average of 0.08 million. At the close of regular trading, its last week’s stock price volatility was 14.04% which for the month reaches 16.51%. ReShape Lifesciences Inc. dipped to as low as $2.48 throughout the day and has returned -88.78% in this year. At one point in the past year, the shares traded as low as $3.01 but has recovered -17.28% since then.
https://postanalyst.com/2018/06/21/could-today-be-a-major-turning-point-bank-of-america-corporation-bac-reshape-lifesciences-inc-rsls/
Recent RSLS News
- ReShape Lifesciences Announces 1-for-58 Reverse Stock Split • GlobeNewswire Inc. • 09/19/2024 12:31:00 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 08/28/2024 08:03:01 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 08/28/2024 08:01:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 08:45:10 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:30:30 PM
- ReShape Lifesciences® Reports Second Quarter Ended June 30, 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 08/14/2024 08:05:00 PM
- ReShape Lifesciences® to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update • GlobeNewswire Inc. • 08/13/2024 12:31:00 PM
- Vyome to go public and trade on the Nasdaq Capital Market under the ticker symbol “HIND” • GlobeNewswire Inc. • 07/09/2024 04:13:13 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 07/09/2024 01:22:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/09/2024 01:21:22 PM
- ReShape Lifesciences® Enters Into Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys • GlobeNewswire Inc. • 07/09/2024 12:31:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2024 09:14:35 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 08:50:53 PM
- ReShape Lifesciences® Reports First Quarter Ended March 31, 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 05/15/2024 08:05:00 PM
- ReShape Lifesciences® to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update • GlobeNewswire Inc. • 05/14/2024 12:31:00 PM
- ReShape Lifesciences® Reports Year Ended December 31, 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 04/01/2024 08:05:00 PM
- ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to an Intragastric Balloon System • GlobeNewswire Inc. • 03/28/2024 12:31:00 PM
- ReShape Lifesciences® Provides Update on 2024 Cost Reduction Plan and Reorganization to Prioritize Commercialization of Lap-Band® 2.0 FLEX • GlobeNewswire Inc. • 03/04/2024 01:31:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 09:19:43 PM
- ReShape Lifesciences® Announces First Surgeries Utilizing Next-Generation Lap-Band® 2.0 FLEX • GlobeNewswire Inc. • 02/22/2024 01:31:00 PM
- ReShape Lifesciences® Conducts Bariatric Fellows Training for its Lap-Band® System, Highlighting the Next-Generation Lap-Band® 2.0 FLEX • GlobeNewswire Inc. • 01/24/2024 01:31:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/18/2024 09:38:03 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/16/2024 11:11:06 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 01/05/2024 09:14:25 PM
- ReShape Lifesciences® Engages Maxim Group LLC To Identify Strategic M&A Partnership Alternatives • GlobeNewswire Inc. • 12/20/2023 01:31:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM